Jun 2026 (Q2 FY26) — Aug 6, 2026
CVRX Q2 FY26 — Lowered Full-Year Guidance Amidst Sales Force and Reimbursement Headwinds
Read the full callCVRX (CVRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CVRX earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 15.7 | +15.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -82.9 | +22.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -14.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.39 +3.73% · +$0.05
Performance −85.1% 1Y
1Y: $9.3 on 14 Oct 2025 → $1.39. High $10.81 (29 Oct 2025), low $1.34 (14 Oct 2026).
- Previous close
- $1.34
- 52-week range
- $1.34 – $10.81
- One year
- −85.55%
Overview
- Symbol
- CVRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CVRX earnings calls (CVRX)
Financials
What the filings say
Net profit, year on year: +5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 15 | 12 | 14 | 15 | 16 | 15 | 16 |
| Operating profit | -13 | -10 | -13 | -14 | -12 | -11 | -12 | -13 |
| Operating margin | −97.3% | −67.0% | −108.8% | −105.8% | −83.5% | −69.8% | −82.3% | −82.9% |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -13 | -11 | -14 | -15 | -13 | -12 | -13 | -14 |
| Tax rate | −0.4% | 0.7% | 0.0% | 0.0% | 0.0% | 0.1% | −0.0% | −0.0% |
| Net profit | -13 | -11 | -14 | -15 | -13 | -12 | -13 | -14 |
| EPS ($ per share) | -0.57 | — | -0.53 | -0.57 | -0.49 | — | -0.50 | -0.53 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -352 | -395 | -436 | -477 | -537 | -591 |
| Total liabilities | 28 | 7 | 16 | 39 | 62 | 65 |
| Fixed assets | 0 | 1 | 2 | 2 | 3 | 2 |
| Total assets | 65 | 153 | 125 | 115 | 133 | 105 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -16 | -28 | -43 | -39 | -39 | -40 |
| Cash from investing | -0 | -1 | -1 | -1 | -1 | -1 |
| Cash from financing | 50 | 112 | 7 | 24 | 56 | 11 |
| Net cash flow | 33 | 83 | -36 | -16 | 15 | -30 |
| Capital expenditure | -0 | -1 | -1 | -1 | -1 | -1 |
| Free cash flow | -16 | -29 | -43 | -40 | -41 | -41 |
Insider filings
30 filings between Nov 6, 2025 and Aug 13, 2026.
Open market
decisions to buy or sellPurchases
$376.8K
3 purchases by 2 insiders
Sales
$927.4K
13 sales by 7 insiders
46% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| JOHNSON & JOHNSON | — | $797.5K | Nov 26, 2025 |
| Jain Mudit K. | $300.4K | — | Feb 20, 2026 |
| Binkowski Brent | $76.4K | $3.3K | Aug 13, 2026 |
| Hykes Kevin | — | $61.3K | Mar 2, 2026 |
| John Robert Allen | — | $31.3K | Mar 2, 2026 |
| OASHEIM JARED | — | $13.8K | Mar 2, 2026 |
| VERRASTRO PAUL | — | $10.1K | Mar 2, 2026 |
| Adamson Philip B. | — | $10.0K | Mar 2, 2026 |
Latest filings (46)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Binkowski Brent CHIEF OPERATING OFFICER | Purchase | 26,223 | $76.4K |
| Aug 12, 2026 | Binkowski Brent CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 1,309 | $3.3K |
| Jun 1, 2026 | Nielsen Kirk G. Director | Award | 8,720 | $0 |
| Jun 1, 2026 | Ballinger Kevin J. Director | Award | 8,720 | $0 |
| Jun 1, 2026 | Jain Mudit K. Director | Award | 8,720 | $0 |
| Jun 1, 2026 | Hill, Mitch C. Director | Award | 8,720 | $0 |
| Jun 1, 2026 | SHADAN MARTHA Director | Award | 8,720 | $0 |
| Jun 1, 2026 | DALE MICHAEL D Director | Award | 29,005 | $0 |
| Jun 1, 2026 | SLATTERY JOSEPH P Director | Award | 8,720 | $0 |
| Mar 2, 2026 | Adamson Philip B. Chief Medical Officer | Sale 10b5-1 plan | 1,262 | $10.0K |
| Mar 2, 2026 | Morrison Gregory CHIEF HUMAN RESOURCES OFFICER | Award | 34,000 | $0 |
| Mar 2, 2026 | John Robert Allen Chief Revenue Officer | Sale 10b5-1 plan | 3,964 | $31.3K |
| Mar 2, 2026 | OASHEIM JARED CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 1,744 | $13.8K |
| Mar 2, 2026 | Hykes Kevin PRES & CEO | Sale 10b5-1 plan | 7,763 | $61.3K |
| Mar 2, 2026 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Sale 10b5-1 plan | 1,284 | $10.1K |
| Feb 27, 2026 | Adamson Philip B. Chief Medical Officer | Award 10b5-1 plan | 41,000 | $0 |
| Feb 27, 2026 | Hykes Kevin PRES & CEO | Award 10b5-1 plan | 159,000 | $0 |
| Feb 27, 2026 | Binkowski Brent CHIEF OPERATING OFFICER | Award | 15,000 | $0 |
| Feb 27, 2026 | OASHEIM JARED CHIEF FINANCIAL OFFICER | Award 10b5-1 plan | 61,000 | $0 |
| Feb 27, 2026 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Award 10b5-1 plan | 45,000 | $0 |
| Feb 27, 2026 | John Robert Allen Chief Revenue Officer | Award 10b5-1 plan | 35,000 | $0 |
| Feb 20, 2026 | Jain Mudit K. Director | Purchase | 46,800 | $297.6K |
| Feb 18, 2026 | Jain Mudit K. Director | Purchase | 600 | $2.8K |
| Nov 26, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 6,337 | $63.6K |
| Nov 25, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 16,000 | $160.5K |
| Nov 24, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 2,200 | $22.1K |
| Nov 21, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 500 | $5.0K |
| Nov 12, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 1,000 | $10.0K |
| Nov 7, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 200 | $2.0K |
| Nov 6, 2025 | JOHNSON & JOHNSON 10% owner | Sale | 52,332 | $534.3K |
| Aug 11, 2025 | Binkowski Brent CHIEF OPERATING OFFICER | Award | 16,600 | $0 |
| May 15, 2025 | Nielsen Kirk G. Director | Purchase | 10,966 | $59.8K |
| May 14, 2025 | Nielsen Kirk G. Director | Purchase | 61,200 | $320.4K |
| May 13, 2025 | Nielsen Kirk G. Director | Purchase | 101,413 | $536.3K |
| May 13, 2025 | Jain Mudit K. Director | Purchase | 150 | $789 |
| May 12, 2025 | Nielsen Kirk G. Director | Purchase | 25,200 | $120.7K |
| May 12, 2025 | Jain Mudit K. Director | Purchase | 1,500 | $7.0K |
| May 12, 2025 | Hykes Kevin PRES & CEO | Purchase | 5,000 | $24.2K |
| Feb 28, 2025 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Award | 16,000 | $0 |
| Feb 28, 2025 | Adamson Philip B. Chief Medical Officer | Award | 20,000 | $0 |
| Feb 28, 2025 | OASHEIM JARED CHIEF FINANCIAL OFFICER | Award | 22,000 | $0 |
| Feb 28, 2025 | Hykes Kevin PRES & CEO | Award | 98,000 | $0 |
| Feb 28, 2025 | John Robert Allen Chief Revenue Officer | Award | 55,000 | $0 |
| Nov 21, 2024 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Gift | 1,040 | $0 |
| Nov 19, 2024 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Option exercise | 2,500 | $12.9K |
| Nov 19, 2024 | VERRASTRO PAUL CHIEF MKTG & STRAT OFFICER | Sale | 1,430 | $19.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CVRx, Inc.
Free account. Everything above stays public.
Write why you follow CVRx, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading